Editorial Board About Us

Jacob Rajfer

All articles from this author are listed below.

Volume 8, Number 1 Literature Reviews

Literature Review

Volume 9, Number 3 Point-Counterpoint

Is Repeat Biopsy for Isolated High-Grade Prostatic Intraepithelial Neoplasia Necessary?

Point-Counterpoint

Arnold I Chin Dhiren S Dave Jacob Rajfer

Numerous studies have cited the positive predictive value of isolated highgrade prostatic intraepithelial neoplasia (HGPIN) to the detection of cancer. Epidemiological, morphological, and molecular data support the potential for malignant transformation of HGPIN, yet no current method can discriminate which lesions will progress to clinically significant prostate cancer versus more latent lesions. Recent analyses of multiple retrospective studies have found similar rates of cancer detection following either diagnosis of isolated HGPIN or an initial negative biopsy. This may reflect increased use of extended biopsy techniques involving 10 or more cores rather than the true ability of HGPIN to undergo malignant transformation. This article discusses controversies surrounding management of an isolated diagnosis of HGPIN and whether repeat biopsy of HGPIN should be mandatory or selective in the context of other predictive values such as rising prostate-specific antigen or lesion on digital rectal examination. [Rev Urol. 2007;9(3):124-131]

Prostate cancer Prostate biopsy Repeat biopsy Prostatic intraepithelial neoplasia (PIN)High-grade PIN

Volume 9, Number 3 Meeting Reviews

Best of the 2007 AUA Annual Meeting

Meeting Review

Jacob Rajfer Michael K Brawer Claus G Roehrborn Dean G Assimos J Curtis Nickel Michael B Chancellor Alan W Partin Ellen Shapiro Danil V Makarov

Highlights from the 2007 Annual Meeting of the American Urological Association May 19-24, 2007 Anaheim, CA [Rev Urol. 2007;9(3):133-154]

Prostate cancer Obesity Benign prostatic hyperplasia Antibiotic prophylaxis Nocturia Lower urinary tract symptoms Botulinum toxin Prostate-specific antigen Biomarkers PCA3 Testosterone Urinary tract infections Urolithiasis Laser ablation Endourology Male voiding dysfunction LHRH antagonists Antimuscarinic agents Circumcision Repeat biopsy Human glandularkallikrein Expectant management CRISP-3 MSP Microvesseldensity Endoglin Survivin Telomeres Interleukin-8 PDE-5 inhibitors Acute urinaryretention 5Alpha-reductase inhibitors Doxazosin Finasteride Transurethral microwave thermotherapy TURP Perioperative blood loss Microbialbiofilms HIV Stem cell injection

Volume 9, Number 3 Literature Reviews

Male Infertility

Reviewing the Literature

Volume 9, Number 1 Point-Counterpoint

Is the Testis a Chemo-Privileged Site? Is There a Blood–Testis Barrier?

Point-Counterpoint

John T Leppert Dhiren S Dave Jacob Rajfer

The incidence of testicular cancer, primarily seminoma, has been increasing in many countries, including the United States. The testis is often the site of residual cancer after adequate treatment with systemic chemotherapy. The blood-testis barrier is commonly cited as the explanation for residual tumor within the gonad after chemotherapy and as the indication for delayed orchiectomy. Conversely, complete eradication of viable tumor from the primary site is common and argues against the testis as a “tumor sanctuary.” Residual tumor is also demonstrated within metastatic foci, and the disparity between the histopathologic response of the primary tumor and metastatic sites may be best explained by tumor heterogeneity and multiple tumor clones. Regardless of the scientific and academic arguments, delayed radical orchiectomy remains an important part of treatment for patients undergoing primary chemotherapy. [Rev Urol. 2007;9(1):28-32]

Chemotherapy Testicular cancer Blood–testis barrier Orchiectomy

Volume 10, Number 3 Meeting Reviews

Advances in Sexual Medicine

Meeting Review

John P Mulhall Jacob Rajfer

Highlights from the 2007 Winter Meeting of the Sexual Medicine Society of North America, December 6-9, 2007, Chicago, IL [Rev Urol. 2008;10(3):232-235]

Radical prostatectomy Erectile dysfunction Phosphodiesterase type 5 inhibitors Stem cells Spinal cord injury Penile implant surgery

Volume 10, Number 2 Literature Reviews

Erectile Dysfunction

News and Views from the Literature

Volume 10, Number 2 Literature Reviews

News and Views from the Literature

Volume 11, Number 4 Meeting Reviews

Best of the 2008 Sexual Medicine Society of North America

Highlights From the Sexual Medicine Society of North America, October 16-19, 2008, Toronto, Ontario, Canada[Rev Urol. 2009;11(4):213-215 doi: 10.3909/riu0466]© 2009 MedReviews®, LLC

Erectile dysfunction Gene splicing PDE5 inhibitors Sexual medicine

Volume 11, Number 3 Case Review

Placenta Percreta and the Urologist

Asghar Askari Ramdev Konijeti Jacob Rajfer

Placenta percreta, the rarest and most severe form of placenta accreta, caninvolve the urinary bladder. Because of its propensity for severe hemorrhage,it is a potentially life-threatening condition. Although commonly discoveredat the time of delivery, antenatal diagnosis may be achieved with ultrasound,magnetic resonance imaging, and/or cystoscopy. Every attempt should bemade to minimize potential for blood loss by avoiding removal of the placentaat the time of delivery and either performing a hysterectomy or usingmethotrexate therapy to ablate the residual placenta in the postpartum period.If hemorrhage does occur during delivery, immediate surgical removalof the uterus should be considered and, depending on the severity of thehemorrhage and the depth of invasion of the placenta into the bladder,excision and/or reconstruction of the bladder may be necessary.[Rev Urol. 2009;11(3):173-176 doi: 10.3909/riu0440]© 2009 MedReviews®, LLC

Placenta percreta Placenta accreta Bladder invasion